{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:29:33Z","timestamp":1761920973155,"version":"build-2065373602"},"reference-count":48,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T00:00:00Z","timestamp":1640217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","doi-asserted-by":"publisher","award":["POCI-01-0145-FEDER-007274","POCI-01-0145-FEDER-029017","Norte-01-0145-FEDER-000051","SFRH\/BD\/146186\/2019"],"award-info":[{"award-number":["POCI-01-0145-FEDER-007274","POCI-01-0145-FEDER-029017","Norte-01-0145-FEDER-000051","SFRH\/BD\/146186\/2019"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Gastric cancer is a serious health problem worldwide. Although its incidence is decreasing, the five-year survival rate remains low. Thus, it is essential to identify new biomarkers that could promote better diagnosis and treatment of patients with gastric cancer. High-mobility group AT-hook 1 (HMGA1) is a non-histone, chromatin-binding protein that has been found overexpressed in several tumor types. It has been correlated with invasion, metastasis, and drug resistance, leading to worse patient survival. The aim of this work was to evaluate the clinical value of HMGA1 in gastric cancer. HMGA1 expression was analyzed by immunohistochemistry in a single hospital series (n = 323) of gastric adenocarcinoma cases (stages I to IV) with clinicopathological and treatment data. In this series, HMGA1 expression showed no significant relevance as a prognostic biomarker. Nevertheless, a significantly better overall survival was observed in cases with high levels of HMGA1 when they were treated with chemotherapy, compared to the nontreated ones, implying that they can benefit more from treatment than patients with low expression of HMGA1. We thereby show for the first time that HMGA1 expression has a substantial value as a biomarker of response to chemotherapy in gastric cancer.<\/jats:p>","DOI":"10.3390\/curroncol29010005","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T21:40:21Z","timestamp":1640295621000},"page":"56-67","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["HMGA1 Has Predictive Value in Response to Chemotherapy in Gastric Cancer"],"prefix":"10.3390","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5780-9842","authenticated-orcid":false,"given":"Diana","family":"P\u00e1dua","sequence":"first","affiliation":[{"name":"i3S\u2014Institute for Research and Innovation in Health, University of Porto, 4200-135 Porto, Portugal"},{"name":"IPATIMUP\u2014Institute of Molecular Pathology and Immunology, University of Porto, 4200-465 Porto, Portugal"},{"name":"ICBAS\u2014Institute of Biomedical Sciences Abel Salazar, University of Porto, 4050-313 Porto, Portugal"}]},{"given":"D\u00e9bora Filipa","family":"Pinto","sequence":"additional","affiliation":[{"name":"i3S\u2014Institute for Research and Innovation in Health, University of Porto, 4200-135 Porto, Portugal"},{"name":"IPATIMUP\u2014Institute of Molecular Pathology and Immunology, University of Porto, 4200-465 Porto, Portugal"}]},{"given":"Paula","family":"Figueira","sequence":"additional","affiliation":[{"name":"i3S\u2014Institute for Research and Innovation in Health, University of Porto, 4200-135 Porto, Portugal"},{"name":"IPATIMUP\u2014Institute of Molecular Pathology and Immunology, University of Porto, 4200-465 Porto, Portugal"}]},{"given":"Carlos Filipe","family":"Pereira","sequence":"additional","affiliation":[{"name":"CNC\u2014Center for Neuroscience and Cell Biology, University of Coimbra, 3004-517 Coimbra, Portugal"},{"name":"Cell Reprogramming in Hematopoiesis and Immunity Laboratory, Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, BMC A12, 221 84 Lund, Sweden"},{"name":"Wallenberg Center for Molecular Medicine, Lund University, 221 84 Lund, Sweden"}]},{"given":"Raquel","family":"Almeida","sequence":"additional","affiliation":[{"name":"i3S\u2014Institute for Research and Innovation in Health, University of Porto, 4200-135 Porto, Portugal"},{"name":"IPATIMUP\u2014Institute of Molecular Pathology and Immunology, University of Porto, 4200-465 Porto, Portugal"},{"name":"Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal"},{"name":"Biology Department, Faculty of Sciences, University of Porto, 4169-007 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4766-9831","authenticated-orcid":false,"given":"Patr\u00edcia","family":"Mesquita","sequence":"additional","affiliation":[{"name":"i3S\u2014Institute for Research and Innovation in Health, University of Porto, 4200-135 Porto, Portugal"},{"name":"IPATIMUP\u2014Institute of Molecular Pathology and Immunology, University of Porto, 4200-465 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/apm.1965.64.1.31","article-title":"The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An Attempt at a Histo-Clinical Classification","volume":"64","year":"1965","journal-title":"Acta Pathol. Microbiol. Scand."},{"key":"ref_3","first-page":"160","article-title":"Histogenesis of intestinal and diffuse types of gastric carcinoma","volume":"180","year":"1991","journal-title":"Scand. J. Gastroenterol. Suppl."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"v38","DOI":"10.1093\/annonc\/mdw350","article-title":"Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Smyth","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1010428317714626","DOI":"10.1177\/1010428317714626","article-title":"Progress in the treatment of advanced gastric cancer","volume":"39","author":"Song","year":"2017","journal-title":"Tumor Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10120-003-0265-0","article-title":"The future of gastric cancer prevention","volume":"7","author":"Correa","year":"2004","journal-title":"Gastric Cancer"},{"key":"ref_7","unstructured":"(2021, November 16). Digestive Cancers Europe (DiCE). Available online: https:\/\/digestivecancers.eu\/gastric-cancer-map\/."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.3748\/wjg.v24.i24.2567","article-title":"Tumor heterogeneity of gastric cancer: From the perspective of tumor-initiating cell","volume":"24","author":"Gao","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000473881","article-title":"Heterogeneity in Gastric Cancer: From Pure Morphology to Molecular Classifications","volume":"85","author":"Gullo","year":"2018","journal-title":"Pathobiology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"7655","DOI":"10.2174\/0929867325666180718164712","article-title":"Cancer Biomarker Discovery for Precision Medicine: New Progress","volume":"26","author":"Zou","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3389\/fcell.2020.00442","article-title":"The Relevance of Transcription Factors in Gastric and Colorectal Cancer Stem Cells Identification and Eradication","volume":"8","author":"Figueira","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41568-019-0196-7","article-title":"Targeting transcription factors in cancer\u2014From undruggable to reality","volume":"19","author":"Bushweller","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"681377","DOI":"10.3389\/fonc.2021.681377","article-title":"Transcription Factors: The Fulcrum Between Cell Development and Carcinogenesis","volume":"11","author":"Islam","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3389\/fcell.2014.00005","article-title":"HMGA proteins as modulators of chromatin structure during transcriptional activation","volume":"2","author":"Ozturk","year":"2014","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Colombo, D.F., Burger, L., Baubec, T., and Sch\u00fcbeler, D. (2017). Binding of high mobility group A proteins to the mammalian genome occurs as a function of AT-content. PLoS Genet., 13.","DOI":"10.1371\/journal.pgen.1007102"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2019.02.022","article-title":"PD-L1 promotes colorectal cancer stem cell expansion by activating HMGA1-dependent signaling pathways","volume":"450","author":"Wei","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.bbrc.2019.06.071","article-title":"HMGA1 promoting gastric cancer oncogenic and glycolytic phenotypes by regulating c-myc expression","volume":"516","author":"Cao","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.2353\/ajpath.2009.090069","article-title":"HMGA1 Is Induced by Wnt\/\u03b2-Catenin Pathway and Maintains Cell Proliferation in Gastric Cancer","volume":"175","author":"Akaboshi","year":"2009","journal-title":"Am. J. Pathol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Parisi, S., Piscitelli, S., Passaro, F., and Russo, T. (2020). HMGA Proteins in Stemness and Differentiation of Embryonic and Adult Stem Cells. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21010362"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Shah, S.N., Kerr, C., Cope, L., Zambidis, E., Liu, C., Hillion, J., Belton, A., Huso, D.L., and Resar, L.M.S. (2012). HMGA1 Reprograms Somatic Cells into Pluripotent Stem Cells by Inducing Stem Cell Transcriptional Networks. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0048533"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/ng.127","article-title":"An embryonic stem cell\u2013like gene expression signature in poorly differentiated aggressive human tumors","volume":"40","author":"Thomson","year":"2008","journal-title":"Nat. Genet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/nrc2271","article-title":"Roles of HMGA proteins in cancer","volume":"7","author":"Fusco","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1111\/jcmm.14082","article-title":"HMGA1 in cancer: Cancer classification by location","volume":"23","author":"Wang","year":"2019","journal-title":"J. Cell. Mol. Med."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Shah, S.N., Cope, L., Poh, W., Belton, A., Roy, S., Talbot, C.C., Sukumar, S., Huso, D.L., and Resar, L.M. (2013). HMGA1: A Master Regulator of Tumor Progression in Triple-Negative Breast Cancer Cells. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0063419"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2174\/1566524016666160316152147","article-title":"The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development","volume":"16","author":"Sumter","year":"2016","journal-title":"Curr. Mol. Med."},{"key":"ref_26","first-page":"567","article-title":"High mobility group A1 and cancer: Potential biomarker and therapeutic target","volume":"27","author":"Shah","year":"2012","journal-title":"Histol. Histopathol."},{"key":"ref_27","first-page":"3642","article-title":"HMGA1 accelerates the malignant progression of gastric cancer through stimulating EMT","volume":"24","author":"Jin","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"16043","DOI":"10.18632\/aging.203130","article-title":"HMGA1 promotes gastric cancer growth and metastasis by transactivating SUZ12 and CCDC43 expression","volume":"13","author":"Yang","year":"2021","journal-title":"Aging"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s11010-015-2384-4","article-title":"Overexpression of HMGA1 correlates with the malignant status and prognosis of breast cancer","volume":"404","author":"Huang","year":"2015","journal-title":"Mol. Cell. Biochem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1046\/j.1365-2559.2003.01618.x","article-title":"Expression of HMGI(Y) associated with malignant phenotype of human gastric tissue","volume":"42","author":"Nam","year":"2003","journal-title":"Histopathology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1158\/0008-5472.CAN-09-1212","article-title":"TheHigh Mobility Group A1Gene: Transforming Inflammatory Signals into Cancer?","volume":"70","author":"Resar","year":"2010","journal-title":"Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"7637","DOI":"10.1158\/1078-0432.CCR-04-0291","article-title":"HMGA1 Protein Overexpression in Human Breast Carcinomas: Correlation with ErbB2 expression","volume":"10","author":"Chiappetta","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/carcin\/bgg075","article-title":"HMGA1 protein over-expression is a frequent feature of epithelial ovarian carcinomas","volume":"24","author":"Masciullo","year":"2003","journal-title":"Carcinogenesis"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41419-018-0683-x","article-title":"HMGA1 exacerbates tumor growth through regulating the cell cycle and accelerates migration\/invasion via targeting miR-221\/222 in cervical cancer","volume":"9","author":"Fu","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.bbcan.2018.03.001","article-title":"High Mobility Group A (HMGA) proteins: Molecular instigators of breast cancer onset and progression","volume":"1869","author":"Sgarra","year":"2018","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1053\/j.gastro.2012.11.033","article-title":"MicroRNA-137, an HMGA1 Target, Suppresses Colorectal Cancer Cell Invasion and Metastasis in Mice by Directly Targeting FMNL2","volume":"144","author":"Liang","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12967-016-0824-x","article-title":"The association between S100A13 and HMGA1 in the modulation of thyroid cancer proliferation and invasion","volume":"14","author":"Zhong","year":"2016","journal-title":"J. Transl. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.2147\/OTT.S197740","article-title":"The proliferation of cervical cancer is promoted by miRNA-125b through the regulation of the HMGA1","volume":"12","author":"Sun","year":"2019","journal-title":"OncoTargets Ther."},{"key":"ref_39","first-page":"1771","article-title":"MicroRNA let-7d-5p rescues ovarian cancer cell apoptosis and restores chemosensitivity by regulating the p53 signaling pathway via HMGA1","volume":"54","author":"Chen","year":"2019","journal-title":"Int. J. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"787","DOI":"10.2147\/CMAR.S289997","article-title":"HCP5 Promotes Proliferation and Contributes to Cisplatin Resistance in Gastric Cancer Through miR-519d\/HMGA1 Axis","volume":"13","author":"Zhang","year":"2021","journal-title":"Cancer Manag. Res."},{"key":"ref_41","first-page":"3771","article-title":"MiR-195 reverses 5-FU resistance through targeting HMGA1 in gastric cancer cells","volume":"23","author":"Wang","year":"2019","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"8267021","DOI":"10.1155\/2019\/8267021","article-title":"Expression and Clinical Relevance of SOX9 in Gastric Cancer","volume":"2019","author":"Mesquita","year":"2019","journal-title":"Dis. Markers"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijsu.2015.10.031","article-title":"HMGA1\/HMGA2 protein expression and prognostic implications in gastric cancer","volume":"24","author":"Jun","year":"2015","journal-title":"Int. J. Surg."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"D\u2019Angelo, D., Mussnich, P., Rosa, R., Bianco, R., Tortora, G., and Fusco, A. (2014). High mobility group A1 protein expression reduces the sensitivity of colon and thyroid cancer cells to antineoplastic drugs. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-851"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5926","DOI":"10.1038\/s41388-018-0394-x","article-title":"HMGA1\/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance","volume":"37","author":"Loria","year":"2018","journal-title":"Oncogene"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00109-017-1520-x","article-title":"Critical role of HMGA proteins in cancer cell chemoresistance","volume":"95","author":"Mussnich","year":"2017","journal-title":"J. Mol. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1506597","article-title":"CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer","volume":"374","author":"Dalerba","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.surg.2020.11.020","article-title":"The utility of high-mobility group A2 overexpression for predicting the prognosis of gastric cancer patients and its contribution to poor prognosis via chemoresistance and the propensity for the occurrence of carcinomatosis peritonei","volume":"169","author":"Lee","year":"2021","journal-title":"Surgery"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/1\/5\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:52:27Z","timestamp":1760169147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/1\/5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,23]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["curroncol29010005"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29010005","relation":{},"ISSN":["1718-7729"],"issn-type":[{"type":"electronic","value":"1718-7729"}],"subject":[],"published":{"date-parts":[[2021,12,23]]}}}